Trial data: iberdomide and mezigdomide activity

Paul reviews response rates, activity in BCMA-exposed and extramedullary disease, and tolerability in trials.

Play episode from 04:55

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!